Company: LGN
Filing Date: 2025-02-14
Form Type: DRS
Source: 0000950123-25-002471
Chunk: 95

Company: Legence Corp.
Filing Date: 2025-02-14
Form: DRS
Chunk 95
---
 the ratio of first lien secured indebtedness (net of cash) to consolidated pro forma adjusted EBITDA for the preceding four fiscal quarters. SOFR loans are subject to a floor of 0.75%. Interest on SOFR loans is payable
(a) based on the selected interest period if such interest period is less than three months or (b) quarterly if the selected interest period is three months or longer. Base rate loans bear interest at a rate equal to either 1.75%, 2.00% or
2.25%, which margin is determined based on the Company’s most recently reported First Lien Net Leverage Ratio, plus the base rate, which is equal to the greater of (a) the federal funds rate plus 0.50%, (b) the prime rate and (c) one-month SOFR plus 1.00%. Interest on base rate loans is payable quarterly. The interest rate applicable to the term loans was %, 8.96%, and 8.13% as of December 31, 2024, December 31,
2023 and December 31, 2022, respectively.

See the section entitled “Management’s Discussion and Analysis of Financial
Condition and Results of Operations—Liquidity and Capital Resources—Debt.”

Assuming no exercise of the underwriters’
option to purchase additional shares, a $1.00 change in the assumed initial public offering price of $ per share (the midpoint of the price range set forth on the cover of this prospectus) would cause the net proceeds
from this offering, after deducting the underwriting discounts and commissions and estimated offering expenses, received by us to change by $ million, assuming no change to the number of shares offered by us, as set forth
on the cover page of this prospectus. Similarly, a one million change in the number of shares sold in this offering by us would cause the net proceeds from this offering, after deducting the underwriting discounts and commissions and estimated
offering expenses, received by us to change by $ million, assuming the initial public offering price of $ per share, which is the midpoint of the estimated public offering price range set forth
on the cover of this prospectus, remains the same. The information discussed above is illustrative only and will adjust based on the actual initial public offering price and other terms of this offering determined at the time of the pricing of this
offering.

60

Confidential Treatment Requested by Legence Corp.

Pursuant to